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G protein coupled receptor (GPCR) kinases (GRKs) are key regulators of GPCR signaling.
Canonical mechanism of GPCR desensitization involves receptor phosphorylation by
GRKs followed by arrestin recruitment and uncoupling from heterotrimeric G protein.
Although b3-adrenergic receptor (b3AR) lacks phosphorylation sites by GRKs, agonist
treatment proved to induce b3AR desensitization in many cell types. Here we show that
GRK2 mediates short-term desensitization of b3AR by a phosphorylation independent
mechanism but mediated by its domain homologous to the regulator of G protein signaling
(RGS). HEK293T cells overexpressing human b3AR presented a short-term
desensitization of cAMP response stimulated by the b3AR agonist, BRL37344, and not
by forskolin. We found that b3AR desensitization was higher in cells co-transfected with
GRK2. Similarly, overexpression of the RGS homology domain but not kinase domain of
GRK2 increased b3AR desensitization. Consistently, stimulation of b3AR increased
interaction between GRK2 and Gas subunit. Furthermore, in rat cardiomyocytes
endogenously expressing b3AR, transfection with dominant negative mutant of RH
domain of GRK2 (GRK2/D110A) increased cAMP response to BRL37344 and inhibited
receptor desensitization. We expect our study to be a starting point for more sophisticated
characterization of the consequences of GRK2 mediated desensitization of the b3AR in
heart function and disease.
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b3-adrenergic receptor (b3AR) was the last member of the b
adrenoreceptors to be identified (Emorine et al., 1989) and
presents a more restrictive expression profile than their
counterparts. It can be found in tissues such as vascular and
intestinal smooth muscle, urinary bladder, kidney tubules, brown
fat and cardiovascular system. Although b3AR agonists are
clinically used only for the treatment of overactive bladder
syndrome (Sacco and Bientinesi, 2012; Igawa and Michel, 2013),
b3AR has been also postulated as a putative target for the treatment
of other diseases such as heart failure (Cannavo and Koch, 2017).
b3ARbelongs to theGprotein-coupled receptor (GPCR) family
characterized by seven transmembrane domains (Emorine et al.,
1989), and can signal throughbothGi andGsprotein dependingon
the tissue and species (Kohout et al., 2001; Pott et al., 2006) and even
in a same cellular context (Gerhardt et al., 1998). It shares only 40–
50% amino acid sequence with other adrenergic subtypes
(Granneman et al., 1993) and its gene comprises one or two
introns depending on the animal species. The first exon encodes
the initial 402 amino acids of the receptor, while the following
encode the last sixor twelve aminoacids in theC-terminus of longer
splice variants (Granneman et al., 1992;Granneman et al., 1993; van
Spronsen et al., 1993). Its C-terminal divergence respect to the other
b-AR subtypes has consequences in its pharmacologic regulation
and its sensitivity to desensitization. Since b3AR lacks potential
phosphorylation sites in its third intracellular loop and C-terminal
tail, it has been thought to be insensitive to cAMP dependent
protein kinase (PKA) or GPCR specific kinases (GRKs) mediated
desensitization, particularly as compared to b1- and b2-
adrenoceptors (Hausdorff et al., 1990). However, phosphorylation
is not the only GRK-mediated mechanism for GPCR
desensitization. Increasing evidence demonstrates that GPCRs
response can be attenuated by proteins with RGS (regulator of G
protein signaling) domain, acting directly on G-proteins by
increasing their GTP hydrolysis rate (GAP activity) or by
precluding Ga-effector interaction when binding to activated Ga
subunit occurs (Evron et al., 2012). GRKs, as members of the RGS
family of proteins, present an N-terminal RGS homology (RH)
domain that has been involved in phosphorylation independent
signaling attenuation of several GPCRs (Sallese et al., 2000; Usui et
al., 2000; Reiter et al., 2001; Dhami et al., 2002; Iwata et al., 2005;
Namkung et al., 2009; Fernandez et al., 2011).
Up to the present, conclusions about susceptibility of b3AR to
agonist-induceddesensitizationdiverge.Reports showedthatb3AR
was resistant to both short term and long term receptor
desensitization in endogenous and heterologous expression
systems (Granneman, 1992; Liggett et al., 1993; Nantel et al.,Abbreviations: AC, adenylyl cyclase; b3AR, b3-adrenergic receptor; FRET, Föster
Energy Transfer; GAP, GTPase accelerating protein; GRK, G protein coupled
receptor kinase; H2R, Histamine receptor type 2; PKA, cAMP dependent protein
kinase; RGS, regulator of G protein signaling; RH; homologous to RGS; siRNA,
small interference RNA.
Chemical compounds studied in this article: BRL37344 (PubChem CID:
9841972); L748337 (PubChem CID: 10028830); Forskolin (PubChem CID:
47936); [3H]CGP-12177 (PubChem CID: 101178785); Amthamine (Pubchem
CID: 126688).
Frontiers in Pharmacology | www.frontiersin.org 21993; Milano et al., 2018). Accordingly, substitution of the second
and third cytoplasmic loops and C-terminal tail of the b3AR with
those of b2AR restored desensitization (Jockers et al., 1996). In
contrast, studies carried out in diverse experimental models have
shown that agonist-induced b3AR desensitization occurs
(Chaudhry and Granneman, 1994; Scarpace et al., 1999;
Hutchinson et al., 2000; Vrydag et al., 2009), and that long term
treatment with isoproterenol induced b3AR-mediated cAMP
response desensitization in HEK293 transfected cells by reducing
the activity of adenylyl cyclase (Vrydag et al., 2009; Michel-Reher
and Michel, 2013; Okeke et al., 2019).
In this context, we aimed to evaluate agonist induced short-term
desensitization of human b3AR expressed inHEK293 cells, and the
underlying mechanism. Pre-exposure of cells to the b3AR agonist,
BRL37344 led to a 40% reduction in cAMP response to the agonist
and not to forskolin. This effect was not attributable to receptor
endocytosis or a reduction in Gs protein levels. We found that
among cardiac GRKs, GRK2 but not GRK5 diminished cAMP
response of b3AR and increased receptor desensitization.
Stimulation of b3AR with BRL37344 increased interaction
between GRK2 and Gas subunit. Overexpression of GRK2 kinase
death mutant or RH domain also increased b3AR desensitization.
Similarly, in rat cardiomyocytes that natively express b3AR,
dominant negative mutant of the RH domain of GRK2 increased
cAMP response to BRL37344 and attenuated desensitization.MATERIALS AND METHODS
Cell Culture
HEK293T (Human embryonic kidney, ATCC® CRL-3216™) cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% foetal bovine serum (FBS) and 5mg/ml
gentamicin at 37°C in humidified atmosphere containing 5% CO2.
Neonatal rat cardiomyocytes were isolated from the heart of 18-
day-old embryos of Sprague-Dawley rats obtained from the animal
facilities of the Facultad de Farmacia y Bioquímica, Universidad de
Buenos Aires. Briefly, after decapitation, hearts were quickly
excised, the atria were cut off, then ventricles were excised and
transferred to fresh ice-cold PBS buffer and were minced with fine
scissors into 1–3 mm3 pieces after washing blood away from the
heart lumen. Theminced tissuewas subjected to digestion six times
in a balanced salt solution containing collagenase type IV (1mg/ml).
The disaggregated cells were collected by centrifugation at 400 g for
5 min and maintained in DMEM-F12 containing 10% FBS, 10mg/
ml insulin, 10mg/ml holo-transferrin, 100mM bromodeoxyuridine
(to prevent proliferation of non-myocyte cells), 10,000U/ml
penicillin and 10mg/ml streptomycin. To reduce the contribution
of non-myocardial cells, cells were pre-plated for 1 h. Themyocyte-
enriched cells remaining in suspension were plated at a density of
0.5×106 cells/well in 12-well plates.
Using this method, we routinely obtain cultures with ≈90–95%
myocytes, as assessed by microscopic observation of rod-shaped
cells spontaneously beating. All animal experiments comply with
the ARRIVE guidelines (Kilkenny et al., 2010) andwere carried out
in accordancewith the guidelines of theNational Institute ofHealth
Guide for theCare andUse of LaboratoryAnimals (2011). All effortsFebruary 2020 | Volume 11 | Article 113
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suffering. This study was approved by the Animal Use and Care
Committee from the Facultad de Farmacia y Bioquímica,
Universidad de Buenos Aires (Res. 4662).
Transient and Stable Transfections
For transient transfections, HEK293T and HEKT Epac-SH187
cells were grown to 80–90% confluency. cDNA constructs were
transfected into cells using K2 Transfection System (Biontex,
Munich, Germany). The transfection protocol was optimized as
recommended by the supplier. Assays were always performed 48
h after transfection. The expression of the constructs was
confirmed by immunoblotting using specific antibodies.
Cardiomyocyteswereplated in12-well cultureplates at a density
of 0.5×106 cells/well in 800ml medium. The day after, cells were
transfected with 1µg of cDNAor 1µg of siRNA constructs using K2
Transfection System (Biontex, Munich, Germany). Twenty-four
hours after transfection, media was replaced. Assays were always
performed 48 h after transfection. The efficacy of the construct was
confirmed by immunoblotting using specific antibodies.
Stable HEK293T expressing pcDNA3.1/Zeo(1)-mTurquoise2-
EPAC-cp173Venus-Venus (Epac-SH187) (HEKT-Epac-SH187) cells
were obtained by transfection of HEK293T using K2 Transfection
System (Biontex, Munich, Germany). Twenty-four hours after
transfection, cells were seeded in the presence of 25µg/ml zeocine
(InvivoGen) for 2 weeks, and clonal selectionwas carried out in 96-
well plates for 2 weeks. Clones were tested for Epac-SH187 by
fluorescence espectra (450–650nm)measurements in a FlexStation
3 Multi-Mode Microplate Reader (Molecular Devices) with
excitation at 430 nm. The HEKT Epac-SH187 clone with higher
fluorescence emission was chosen for further experiments. The
stable clonewas grown inDMEMmedium supplementedwith 10%
FBS, 50 mg/ml gentamicin and 12.5 mg/ml zeocin.
Plasmid and siRNA Constructions
Histamine type 2 receptor (H2R), GRK2, and GRK5 cDNAs were
previously subcloned into the pCEFL vector (pCEFL H2R, pCEFL
GRK2, and pCEFL GRK5) in our laboratory (Shayo et al., 2001).
pCEFLHA RHPH construct derived from GRK2 was previously
obtained inour laboratory (Fernandez et al., 2011). pCDNA3.1HA-
b3-adrenergic receptor of human origin was obtained from
Missouri S&T cDNA Resource Center (Rolla, MO). pcDNA3
GRK2-D110A was kindly provided by Dr. R. Sterne-Marr
(Biology Dept., Siena College, Loudonville, NY). pcDNA3 GRK2-
K220R and pcDNA3 GRK2-R106A/K220R were a kind gift from
Dr. J. Benovic (Thomas Jefferson University, Microbiology and
Immunology Department, Kimmel Cancer Center, Philadelphia).
Rat b3AR siRNA (CAACAGGUUUUGAUGGCUAU) and Non-
Targeting siRNA (UAAGGCUAUGAAGAGAUAC) was
purchased to Horizon Discovery Ltd. (Cambridge, UK). The
mTurquoise2-EPAC-cp173Venus-Venus (Epac-SH187) construct
was provided by Dr. KeesJalink (Cell Biophysics & Imaging
Group, Netherlands Cancer Institute) (Klarenbeek et al., 2015).
Western Blot Assays
For western blot assays, cells were lysed in 50mMTris-HCl pH 6.8,
2% SDS, 100mM 2-mercaptoethanol, 10% glycerol and 0.05%Frontiers in Pharmacology | www.frontiersin.org 3bromophenol blue and sonicated to shear DNA. Total cell lysates
were resolved by SDS-PAGE. Blots were incubated with primary
anti: HA, b-tubulin, Gas/olf, GRK2, and GRK5 antibodies (Santa
Cruz Biotechnology, CA; see materials for details), followed by
horseradish peroxidase conjugated anti-rabbit or anti-mouse
antibodies (Vector Laboratories, CA; see materials for details) and
developed by enhanced chemiluminesence (ECL) following the
manufacturer’s instructions (Amersham Life Science, England).
Immunofluorescence
HEK293T cells were washed with PBS 48 h after transfection
with pCDNA3.1-HA b3AR or empty vector and fixed in 2%
formaldehyde in PBS for 10 min. The non-specific binding sites
were blocked for 30 min with blocking solution (PBS containing
1% BSA). Then cells were incubated for 1 h at room temperature
with the anti-HAantibody (1:50). FollowingwashingwithPBS, cells
were incubated with secondary Alexa488-conjugated antibody
1:250 for 1 h at room temperature. Donkey Alexa488-conjugated
IgG (Jackson ImmunoResearch Laboratories Inc.,West Grove, PA)
cat # 711-545-152 secondary antibody was used to detect rabbit
primary antibody. After washingwith PBS, the cells were incubated
withHoechst 33258 nucleic acid stain (1mg/mL) for 10min. Finally,
the coverslips were washed with PBS and mounted on glass slides
withmountingmedium. Imageswere acquiredusing a spectral laser
scanning confocal Zeiss LSM800 fluorescent microscope (63X
apochromatic, 1.4 NA objective) using dual excitation (493 nm
for Alexa488 and 405 nm for Hoechst). Controls prepared by
omission of primary antibody did not show any Alexa488
fluorescence under the above conditions.
cAMP Radiobinding Protein Assay
For cAMP studies, HEK293T transfected cells were plated at
2x105cells/cm2 in 48 wells plates. Two replicates per condition
were performed in each independent experiment. Cardiomyocytes
were maintained in 12 wells plate at an approximate density of
1.25x105cells/cm2. Three replicates per condition were performed
in each independent experiment.
For time-course cAMP accumulation experiments, cells were
incubated 3 min in basal media supplemented with 1mM IBMX
and exposed for different periods of time to 10µM BRL37344.
For response assays, cells were incubated 3 min in basal
culture medium supplemented with 1mM IBMX at 37°C,
followed by exposure to different concentrations of BRL37344
or forskolin for 30 min.
For b3AR blockade assays, cells were incubated 3 min in basal
media supplemented with 1mM IBMX and 10µM L748337, and
then exposed for 30 min to 1µM and 10µM BRL37344.
For desensitization assays, cells were pre-treated with 10µM
BRL37344 in the absence of IBMX for different periods of time as
shown in the figures. Cells were thoroughly washed and
resuspended in fresh medium containing 1mM IBMX, incubated
for 3min, and exposed to 10µMBRL37344 for 30min to determine
whether the system was able to generate a cAMP response.
In all experiments, the reaction was stopped by ethanol
addition followed by centrifugation at 3,000g for 5 min. The
ethanol phase was then dried, and the residue resuspended in
50mM Tris-HCl pH 7.4, 0.1% BSA. cAMP content wasFebruary 2020 | Volume 11 | Article 113
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described (Davio et al., 1995).
FRET Time-Course of cAMP Intracellular
Levels With Flex Station 3
FRET time-course of cAMP intracellular levels was measured as
previously described (Carozzo et al., 2019). Briefly, HEKT Epac-
SH187 transfected with pCDNA3.1 HA-b3-adrenergic receptor
alone or with pCEFL GRK2 pC were seeded in 96-well plates at a
density of 1 x 105 cells/well. Before starting each experiment, cells
were washed with NaCl 0.9% twice and 100 ml of FluoroBrite
DMEM (Thermofisher) was added to each well before placing the
plate inaFlexStation®3 at 37°C. Inorder todetermine intracellular-
cAMP (i-cAMP) response, we measured the baseline fluorescence
signal detected at 475 nm (donor) and 530 nm (FRET) emission
with excitationat 430nm.Using theon-boardpipettor,weadded50
ml of 3XBRL37344 after 40 s and thenmonitored the signal every 20
s for a total of 600 s. Different concentrations of BRL37344 were
assayed for each transfection. FRET and donor intensities were
measured for each timepoint. FRET/donor ratiowas calculated and
normalized to basal levels -before stimulation- (R/R0) for each time
point. An AUC value of 10-minute R/R0 i-cAMP response was
calculated for each replicate. Concentration-response curves were
constructed plotting AUC values of 10-minute R/R0 i-cAMP
response vs log [BRL37344].
Radioligand Binding Assay
For binding assays, HEK293T cells transfected with pCDNA3.1
empty vector or pCDNA3.1 HA-b3-adrenergic receptor were
seeded in 48 well plates at 7x104 cells/well. The number of
binding sites was evaluated by radioligand binding assay using
[3H]-GCP12177 (30Ci/mmol) in the presence or absence of 8µM
L748337 at 4°C. Binding in whole cells was performed at 4°C to
avoid ligand internalization, as previously described (Tubio et al.,
2010). The incubation was stopped by rapid washing with ice-
cold physiologic solution (0.9% NaCl). After three washes, the
bound fraction was collected in 200ml of ethanol, and Optiphase
HiSafe3 scintillation cocktail was added to each fraction for
counting in a HIDEX 300 SL counter.
To evaluate possible receptor internalization, transfected
HEK293T cells were incubated 1 h with 10µM BRL37344 at
37°C, and after washing, the number of receptor sites was
analyzed by radioligand binding assay.
Quantitative RT-PCR
Total RNA was extracted from cardiomyocytes using Quick-Zol
reagent (Kalium Technologies, Buenos Aires, Argentina) and
reverse-transcribed using the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, CA) following the
manufacturer’s instructions. Quantitative RT-PCR (qPCR) was
performed in triplicate using HOT FIREPol EvaGreen qPCRMix
Plus (Solis Biodyne, Tartu, Estonia) and a Rotor Gene Q
detection system (Qiagen, Hilden, Germany), cycling
parameters were as follows: 15 min at 95°C and 45 cycles of
30 s at 94°C, 30 s at 60°C, and 30 s at 72°C. The relative b3AR
mRNA quantification was performed with the comparative DDCt
method using b-actin as the housekeeping gene.Frontiers in Pharmacology | www.frontiersin.org 4Co-Immunoprecipitation
HEK293T cells plated in 100mm dishes were co-transfected with
b3AR, HA-Gas and wild type GRK2 as indicated. 48 h after
transfection cells were starved for 1 h, washed with PBS and
incubated for 1 h at 37°C in PBS with 10µM BRL37344. Cross-
linking was done in intact cells by replacement of stimuli by 3ml
of PBS with 2.5 mM dithiobis(succinimidyl propionate) (DSP)
(Pierce) with 10µM BRL37344 and incubation for 30 min at 25°
C. DSP was washed with PBS and cells were solubilized in 1ml of
radioimmune precipitation assay buffer (1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 50mM Tris, pH 7.4, 100mM
NaCl, 2mM EDTA, 50mM NaF, 1mM phenylmethylsulfonyl,
5µM aprotinin, 10µM leupeptin, 5µM pepstatin, 1mM sodium
vanadate) at 4°C for 30 min, and immunoprecipitation of GRK2
was done by 2 h incubation with the specific anti-GRK2 antibody
at 4°C. Immunocomplexes were recovered by overnight incubation
with Protein A/G Plus-Agarose (Santa Cruz Biotechnology) and
washed 4 times with ice-cold immunoprecipitation buffer.
Separation of immune complexes and cleavage of the cross-linker
was done for 90 min at 37°C in Laemmli buffer .
Immunoprecipitated proteins were resolved by SDS-PAGE and
transferred to nitrocellulose membranes. HA-Gas and GRK2 were
detected with a rabbit anti-HA antibody, rabbit anti-Gas antibody
or rabbit anti-GRK2 antibody as described below.
Data and Statistical Analysis
Numbers (n) for all experiments are provided in corresponding
figures legends and refer to independentmeasurements. In general,
n=5 was used for concluding about mechanisms of action and n=3
was used for setting working conditions, characterizing ourmodels
or when different approaches of the same event (orthogonal assays)
were followed. Data are presented as mean ± standard deviation
(SD). Fittings of sigmoidal concentration-response, desensitization
and binding saturation assay; and comparison of best fit values
according to extra-sum of squares F test were performed with
GraphPad Prism 6.00 for Windows, GraphPad Software (San
Diego, CA). In radioligand binding assays specific binding was
calculated by subtraction of nonspecific binding from total binding.
For western blot data analysis, films were scanned and quantified
using ImageJ software fromNational Institutes ofHealth (NIH) for
the densitometry analysis of bands. For quantification, the
background value of the scanned gel was subtracted, and the
relative abundance was achieved by relativizing protein content to
b-tubulin. Relative abundance was then normalized respect to
control group.
Statistical analysis was carried out by one or two-sided Students’
t-test, one or two-way-ANOVA followed byBonferroni orDunnett
post-test as indicated. Post hoc tests were run only if overall
statistically significant difference between means were obtained.
Statistical significance was accepted when P < 0.05. Statistics were
performed usingGraphPad 6.00 forWindows, GraphPad Software
(San Diego, CA).
Materials
Cell culture medium, antibiotics, isobutyl methylxanthine (IBMX),
cAMP, bovine serum albumin (BSA), BRL37344, forskolin,
L748337, amthamine, bromodeoxyuridine, holo-transferrinFebruary 2020 | Volume 11 | Article 113
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inhibitorswereobtained fromSigmaChemicalCompany (St. Louis,
MO). Dithiobis(succinimidyl propionate) (DSP) was from Pierce
(Rockford, USA). FluoroBrite DMEM from Gibco was purchased
from TermoFisher Scientific (New York, USA). [3H]cAMP, [3H]
(-)-CGP-12177 and Optiphase HiSafe3 scintillation cocktail were
purchased from Perkin Elmer Life Sciences (Boston, MA). Foetal
bovine serumwas fromNatocor (Córdoba,Argentina).Collagenase
(type IV) was obtained fromWorthington, (Lakewood, NJ). Other
chemicals used were of analytical grade and obtained from
standard sources.
Protein A/G Plus-Agarose (catalogue#SC-2003/Lot#J0118/
Santa Cruz Biotechnology, CA)
The following primary antibodies were purchased from Santa
Cruz Biotechnology, CA:
Anti-HA antibody (IgG from rabbit/catalogue#SC-805/
Lot#K1915/final dilution: 1/500 for WB and 1/50 for
immunofluorescence)
Anti-b-tubulin antibody (IgG from rabbit/catalogue#SC-9104/
Lot#F1210/final dilution: 1/500)
Anti-GRK2 antibody (IgG from rabbit/catalogue#SC-562/
Lot#F1610/final dilution: 1/1000)
Anti-GRK5 antibody (IgG from rabbit/catalogue#SC-565/
Lot#D1210/final dilution: 1/400)
Anti-Gas antibody (IgG from rabbit/catalogue#SC-383/
Lot#L309/final dilution: 1/500)
The following secondary antibodies were purchased from
Vector Laboratories, CA:
Anti-rabbit antibody (IgG from goat/catalogue#PI1000/
Lot#X0126/final dilution: 1/4000)
Anti-mouse antibody (IgG from horse/catalogue#PI2000/
Lot#W0218/final dilution: 1/2000)
Anti-rabbit antibody Alexa488-conjugated (IgG from donkey/
cat # 711-545-152) was from Jackson ImmunoResearch
Laboratories Inc., West Grove, PA)






Characterization of Human b3AR
Response to BRL37344 in HEK293T
Transfected Cells
We initiated the study of the desensitization mechanisms of
b3AR in a heterologous expression model, b3AR transfected
HEK293T cells. In HEK293T cells transiently transfected withFrontiers in Pharmacology | www.frontiersin.org 5Mock or pCDNA3.1HA-b3AR (HEK293T-b3AR cells) we
evaluated receptor expression by binding experiments using
[3H]CGP-12177 a ligand for b1/2/3ARs commonly used as a
general b blocker (Vrydag and Michel, 2007; Suarez et al., 2014;
Gherbi et al., 2015; Littmann et al., 2015). We found a three-fold
increase in [3H]CGP-12177 binding sites in HEK293T-b3AR
(3024 ± 172) respect to Mock transfected cells (902 ± 50) (Figure
1A) and a right shift in Kd from 12.8 ± 3.2 to 85.9 ± 14.3. These
results indicate the heterologous overexpression of the
transfected b3AR in HEK293T cells.
In a first attempt to time-resolve cAMP response of b3AR,
HEK293T-b3ARcellswere stimulatedduringdifferent timeperiods
with the b3AR agonist, BRL37344 (Alexander et al., 2013) in
presence of IBMX (phosphodiesterase inhibitor), and cAMP
accumulation was determined. Maximal cAMP levels were
reached after 30 min treatment (Figure 1B). Considering this,
concentration-response experimentswere doneby stimulating cells
for 30 min with BRL37344. In Mock transfected HEK293T cells,
Rmax to BRL37344was 4.5 ± 1.7 pmol/150,000 cells. As expected, a
significantly higher production of cAMP was observed in
HEK293T-b3AR cells, where Rmax was 21.4 ± 0.5 pmol/150,000
cells (P < 0.05) (Figure 1C). These results indicate that in our
system, endogenously expressed receptors and transfected HA-
b3AR behave similar, with both concentration-response curves
fitting to a model showing a common pEC50 value of 6.79 ± 0.17,
whereas the maximal response was approximately 5-fold higher in
HEK293T-b3AR cells. Pre-treatment with L748337, a specific
b3AR ligand commonly used as b3AR blocker (Sato et al., 2008;
Alexander et al., 2013) although led to a low increase in cAMPbasal
levels, completely impeded cAMP increased in response to
BRL37344 (Figure 1D), confirming that in our system, the
observed cAMP response to BRL37344 is specifically due to
b3AR stimulus.
Short-Term Desensitization of Human
b3AR in HEK293T Transfected Cells
To evaluate the effect of agonist pre-treatment on b3AR
responsiveness, HEK293T-b3AR cells were pre-incubated with
10µM BRL37344 for a period ranging from 0 to 210 min. The
pre-exposure of HEK293T-b3AR cells to BRL37344 although
slightly increased basal levels notably diminished cAMP
production when cells were re-challenged with the same agonist
(Figure 2A left panel). Plateau response induced by BRL37344 was
almost 59 ± 13% (Figure 2A right panel) of the control response of
45.9 ± 2.7 pmol/250,000 cells, and halfmaximal desensitizationwas
observed at 27 min (Figure 2A). These results were confirmed by
concentration-response assays in control or 1h pre-treated
HEK293T-b3AR cells. Pre-treatment of the cells with 10µM
BRL37344 significantly diminished concentration dependent
response to BRL37344 with Rmax varying from 21.5 ± 0.9pmol/
150,000 cells to 16.0 ± 0.7pmol/150,000 cells (P < 0.05) (Figure 2B).
Interestingly, cAMP response to forskolin, a direct activator of
adenylyl cyclase, was not decreased by pre-treatment of cells
(Figure 2C). This result indicates that the events involved in the
attenuation of b3AR response takes place upstream AC activation.
A reduction in Gas protein levels upon 24 h treatment with
isoprenaline was described by other authors in HEK293 cellsFebruary 2020 | Volume 11 | Article 113
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BRL37344 did not reduce immunoreactivity of Gas in HEK293T-
b3AR (Figure 2D). Since b3AR can also couple to Gai (Chaudhry
and Granneman, 1994; Pott et al., 2006) we evaluated whether
changes in receptor coupling to G protein could be responsible forFrontiers in Pharmacology | www.frontiersin.org 6the diminished cAMP response to BRL37344 observed after pre-
exposure to the agonist. Inhibition of Gai protein by pre-treatment
of HEK293T-b3AR cells with pertussis toxin (PTX) although
increase basal cAMP levels did not prevent desensitization of
cAMP response after pre-exposure to BRL37344 (Figure 2E).FIGURE 1 | Characterization of cAMP response to b3AR stimulation. (A) HEK293T cells transfected with Mock or b3AR were incubated with different
concentrations of 3[H]-CGP12177 as stated in Materials and Methods. Data represent mean ± SD (n=3). Best-fit values of the parameters are in the main text.
Comparison of Kd and Bmax from both binding curves were done by extra sum of squares F-test. (B) HEK293T Mock or b3AR transfected cells were treated during
different time periods with 10µM BRL37344, in presence of IBMX. Data represent mean ± SD (n=3). (C) HEK293T Mock or b3AR transfected cells were pre-treated
with IBMX for 3 min and stimulated with indicated concentrations of BRL37344 for 30 min. Data represent mean ± SD (n=3). Best-fit values of the parameters are in
the main text. (D) Effect of 10µM L748337 (L7) over basal or stimulated cAMP levels in response to 1mM or 10µM BRL37344 (BRL) in HEK293T Mock or b3AR
transfected cells. Each data point represents a single experiment and data in absence or presence of L7 from the same experimental day are connected by lines
(n=3). Data were analyzed by two-way ANOVA followed by Bonferroni post-test. ns, not significant; *P < 0.05; ***P < 0.001 respect to Ctrol. ns, not significant;
#P < 0.05; ###P < 0.001 as indicated. cAMP accumulation was quantified as described under Materials and Methods.February 2020 | Volume 11 | Article 113
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Signaling Regulation
To determine whether the decrease in cAMP response in pre-
treated cells was due to a reduction in b3AR sites we carried outFrontiers in Pharmacology | www.frontiersin.org 7binding experiments using [3H]CGP-12177. Results
demonstrated that 1h pre-treatment with 10µM BRL37344 did
not alter the density of [3H]CGP-12177 binding sites in
HEK293T-b3AR cell membranes, showing a global Bmax ofFIGURE 2 | Desensitization of b3AR cAMP response. (A) HEK293T-b3AR cells were pre-treated during different time-periods with 10µM BRL37344. After that, cells
were washed, incubated with IBMX for 3 min and challenged (stimulated response) or not (basal response) with 10µM BRL37344 for 30 min. cAMP levels are
expressed as picomols over 250000 cells (left panel) or as the ratio of stimulated over basal cAMP (S/B) respect to control (without pre-treatment) which is
considered as 100% (right panel). Data represent mean ± SD (n=5). Best-fit values of the parameters are in the main text. (B) HEK293T-b3AR cells were pre-treated
with 10µM BRL37344 for 1h or not and stimulated with different concentrations of BRL37344. Data represent mean ± SD (n=5). Best-fit values of the parameters are
in the main text. (C) HEK293T-b3AR cells were pre-treated with 10µM BRL37344 for 1h or not and stimulated with different concentrations of forskolin (Fsk) for 30
min. Each data point represents the mean of a single experiment and cAMP response in untreated or pre-treated cells from the same experimental day are
connected by lines (n=5). ns indicates not significant differences respect to Ctrol analyzed by two-way ANOVA followed by Bonferroni post-test. ns, not significant;
#P < 0.05; ###P < 0.001 as indicated. (D) HEK293T-b3AR cells were pre-treated with 10µM BRL37344 for 1h or not, lysed, resolved by 12% SDS-PAGE and
immunoblotted using anti-Gas antibody. A representative image is showed. Densitometry analysis was performed with ImageJ as indicated in Materials and Methods
and analyzed by student t-test comparing Gas levels in 1 h pre-treated vs control cells (n=3). (E) Basal or 10µM BRL37344 stimulated cAMP levels were determined
in control or desensitized HEK293T-b3AR cells treated with PTX 100ng/mL or vehicle for 3h. Data represent mean ± SD. Each data point represents the mean of a
single experiment and cAMP response in untreated or BRL37344 pre-treated cells from the same experimental day are connected by lines (n=3). Data were
analyzed by two-way ANOVA followed by Bonferroni post-test. *P < 0.05; **P < 0.01; ***P < 0.001 respect to Ctrol. #P < 0.05; ##P < 0.01 as indicated. cAMP
production was quantified as described under Materials and Methods.February 2020 | Volume 11 | Article 113
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immunofluorescence assays we observed by confocal microscopy
of HEK293T-b3AR that HA-b3AR was present at the plasma
membrane. In cells treated for 1h with 10µM BRL37344, no
change in the subcellular distribution of b3AR was observed
(Figure 3B). These results indicate that pre-treatment with
BRL37344 does not lead to internalization of b3AR sites.
Considering that GRKs are determinants of GPCR signaling
and taking into account that GRK2 and GRK5 are the most
abundant GRKs in the cardiovascular system (Harris et al., 2008;
Dorn, 2009) where a cardioprotective role was conferred to
b3AR agonism (Dessy and Balligand, 2010; Niu et al., 2012;
Cannavo and Koch, 2017) we investigated whether these proteins
were involved in b3AR desensitization. Concentration–response
experiments were carried out after 30 min stimulation with
increasing concentrations of BRL37344 in HEK293T-b3AR
cells co-transfected alternatively with GRK2 or GRK5 constructs.
We observed that althoughb3ARoverexpression is not alteredwhen
co-transfected with either GRK2 or GRK5 (Figure 3C) the cAMP
response of the receptor varied depending on the subtype of GRK
overexpressed (Figure 3D). GRK2 overexpression but not GRK5
significantly decreased concentration dependent response to
BRL37344 in a 27 ± 2% respect to HEK293T-b3AR control cell
(P<0.05) (Figure3D). Since cAMPaccumulation studies inpresence
of IBMX have been recently questioned based on the possibility that
accumulating cAMP might leave the cells and act on adenosine
receptors lowering intracellular cAMP levels (Okeke et al., 2019), we
confirmed our studies using FRET based determinations to
quantified real-time intracellular cAMP (i-cAMP) levels without
IBMX (Figure 3E). Using this methodology, we observed a more
pronounced effect of GRK2 overexpression and/or pre-exposure to
the agonist over cAMP production in response to b3AR stimulation.
RGS-Mediated Regulation of Human b3AR
in HEK293T Transfected Cells
We have previously reported that the regulator of G-protein
signaling (RGS) homology domain of GRK2 (RH) is sufficient to
mediate the desensitization of a Gas coupled GPCR, the histamine
type 2 receptor (H2R) (Fernandez et al., 2011). Moreover, RH has
been involved in phosphorylation independent signaling
attenuation of several GPCRs (Sallese et al., 2000; Usui et al.,
2000; Reiter et al., 2001; Dhami et al., 2002; Iwata et al., 2005;
Namkunget al., 2009; Fernandez et al., 2011;Echeverria et al., 2019).
Whencells are stimulatedwith10µMBRL37344adirect interaction
between wild type GRK2 and HA-Gas is observed by co-
immunoprecipitation assay (Figure 4A). Based on these
observations and given that b3AR was described to be not
susceptible to phosphorylation, we explored the influence of RH
domain of GRK2 in the regulation of b3AR responsiveness.
Time-course desensitization experiments were performed
through cAMP levels determinations in HEK293T-b3AR cells co-
transfectedwithGRK2wild type or dominant negativemutants for
kinase (GRK2-K220R) or RH (GRK2-D110A) or both (GRK2-
R106A/K220R). For this, cells were pre-treated with agonist during
different periods of time and re-challenged with the same ligand.
The expression of the different GRK2 variants was detected by
western blot (Figure 4B upper panel). In HEK293T-b3AR cellsFrontiers in Pharmacology | www.frontiersin.org 8overexpressing GRK2, pre-treatment with BRL37344 decreased
cAMP response of b3AR to a re-challenge with the agonist in a
more pronounce manner than in HEK293T-b3AR control cells
(Figure 4B lower panel). While HEK293T-b3AR control cells
reached a plateau of 61.03 ± 3.53% of the control response,
cells overexpressing GRK2 presented a significantly lower plateau
of 21.62 ± 3.34% of the control response (P < 0.01), showing an
inhibition in the response to BRL37344. In the same way,
overexpression of GRK2-K220R (kinase inactive) or the RH
domain fused to the C-terminal PH domain of GRK2 (RHPH)
also increased b3AR desensitization, leading to a residual response
withaplateauof27.70±4.71%(P<0.01)or49.37±3.39%(P<0.05)
of the control response respectively. On the contrary,
overexpression of variants with mutated RH domain GRK2-
D110A or GRK2-R106A/K220R although tended to diminish
b3AR desensitization 74.06 ± 15.86% and 73.16 ± 9.21 showed no
significant differences in the residual response respect to the control
cells (Figure 4B lower panel).
These results point to the RH domain of GRK2 as responsible
for b3AR desensitization and indicate that a functional RH
domain of GRK2 is necessary to achieve complete b3AR
desensitization. Based on that, we next evaluated whether
prolonged activation of other Gas coupled GPCR as the H2R
may also lead to b3AR desensitization. Pre-treatment of cells for
1h with H2R agonist amthamine 10µM although led to H2R
desensitization (data not shown) did not modify b3AR cAMP
response to BRL37344 (Figure 4C).
RH-Mediated Regulation of Endogenous
b3AR in Neonatal Rat Cardiomyocytes
Cardiac b3AR over-expression and signaling proved to be a
cardioprotective event in patients with heart failure (Niu et al.,
2012). Based on that, we aimed to evaluate whether interruption
of the desensitization mediated by the RH domain of GRK2
allows an increased response of b3AR in a primary culture of rat
cardiomyocytes. Since there is a minority cardiac expression of
b3AR respect to that of b1AR or b2AR (Pott et al., 2006), we first
analyzed the specificity of the cAMP response to BRL37344. In
primary cultured rat cardiomyocytes, while 1µM BRL37344 did
not significantly increase cAMP levels, stimulation with 10µM
BRL37344 led to a significant cAMP response that was inhibited
by L748337 (Figure 5A). Cardiomyocytes transfected with
siRNA for b3AR, that led to knockdown of receptor levels to
undetectable amounts by qPCR (Figure 5B table), showed no
cAMP production after stimuli with 10µM BRL37344,
confirming the specificity of the evaluated response (Figure 5B).
Transfection of cardiomyocytes with GRK2-K220R mutant
lacking kinase activity but with intact RH domain (Figure 5C), did
not modify cAMP response to BRL37344 (Figure 5D) while
transfection with GRK2-D110A (Figure 5E) significantly
augmented cAMP response to 10µM BRL37344 (Figure 5F). In the
same way, 30 min pre-treatment of cardiomyocytes with 1µM
BRL37344, significantly diminished the capacity of response to
BRL37344 (Figure 5G) indicating b3AR desensitization. However,
in desensitizedmyocytes cAMP response to BRL37344was higher in
cells transfected with GRK2-D110A than in Mock transfected cells
(Figure 5G). These results indicate that inhibition of RGS activity ofFebruary 2020 | Volume 11 | Article 113
Echeverría et al. Regulation of b3-Adrenergic Receptor Signaling by GRK2FIGURE 3 | Mechanisms of regulation of b3AR cAMP response. (A) HEK293T-b3AR cells were pre-treated with 10µM BRL37344 for 1h or not, washed and
incubated with different concentrations of 3[H]-CGP12177 as stated in Materials and Methods. Data represent mean ± SD (n=3). Best-fit values of the parameters
are in the main text. Comparisons of Bmax from both binding curves were done by extra sum of squares F-test. (B) HEK293T cells transfected with HAb3AR were
pre-treated with 10µM BRL37344 for 1h or not, washed and fixed for immunocytochemical staining as described under Materials and Methods. Images of
fluorescence signal corresponding to secondary Alexa488-conjugated antibody, nuclear Hoechst 33258 staining and merged images are shown. The
immunostaining obtained with the anti-HA tag antibody indicated expression and location of HAb3AR in HEK293T cells after transfection. Images are representative
of 3 independent experiments. (C) HEK293T-b3AR cells co-transfected with GRK2 or GRK5 were lysed, resolved by 12% SDS-PAGE and immunoblotted using
anti-GRK2, anti-GRK5, anti-HA or anti-b tubulin antibodies. A representative image is showed. Densitometry analysis was performed with ImageJ as indicated in
Materials and Methods and analyzed by student t-test comparing HA-b3AR levels in GRK2 or GRK5 co-transfected cells vs HA-b3AR without GRKs which was
considered as 100%. Results are mean ± SD (n=5). (D) HEK293T-b3AR cells co-transfected with GRK2 or GRK5, were pre-treated with IBMX for 3 min and
stimulated with different concentrations of BRL37344 for 30 min. Upper panel: results are expressed as % respect to maximal response of control (b3AR without
GRKs), data represent mean ± SD (n=5). Lower panels: Raw data of the maximal cAMP levels from each individual experiment are shown. Data were analyzed by
paired student t-test. ns, not significant; *P < 0.05 respect to b3AR. cAMP production was quantified as described under Materials and Methods. (E) HEKT Epac-
SH187 transiently co-transfected with b3AR and GRK2 wild type were pre-treated during 1 h with either 10µM BRL37344 or vehicle. After that, cells were washed
and challenged with different concentrations of BRL37344. Concentration-response curves were constructed with the AUC values of 10-minute R/R0 i-cAMP
response of time course of FRET changes determined in FlexStation® 3 at 37°C as described in Materials and Methods (left). HEKT Epac-SH187 co-transfected with
b3AR and GRK2 wild type, were lysed, resolved by SDS-PAGE 12% and immunoblotted using anti GRK2 or anti-b tubulin antibodies as indicated. Image showed is
representative of three independent experiments (right).Frontiers in Pharmacology | www.frontiersin.org February 2020 | Volume 11 | Article 1139
Echeverría et al. Regulation of b3-Adrenergic Receptor Signaling by GRK2GRK2allows ahigherb3ARsignaling andpoints outRHdomain as a
relevant regulator of b3AR response in the cardiac context.DISCUSSION
For a long time, b3AR has been thought to be insensitive to PKA or
GRK mediated desensitization due to the lack of potential
phosphorylation sites in its third intracellular loop and c-terminal
tail that are indeed present in b1AR and b2AR variants. This
observation was confirmed by results obtained using chimeric b2/
3-AR (Hausdorff et al., 1990; Liggett et al., 1993; Jockers et al., 1996).Frontiers in Pharmacology | www.frontiersin.org 10However, experiments carried out in heterologous expression
systems allowed to describe that long-term stimulation of human
b3AR leads to attenuation of receptor response in HEK293
transfected cells (Vrydag et al., 2009; Michel-Reher and Michel,
2013; Okeke et al., 2019). Results presented in this work show that
human b3AR heterologously expressed in HEK293T cells is
sensitive to short-term desensitization by a mechanism that takes
place upstream AC activation and does not involve Gas
downregulation nor a switch in receptor coupling to Gai. Instead,
it proved to depend on the integrity of the RH domain of GRK2.
RGS family of proteins regulates GPCR signaling through two
general mechanisms. One involves its GAP (GTPase-acceleratingFIGURE 4 | GRK2-mediated desensitization of human b3AR. (A) Co-immunoprecipitation of Gas and GRK2 is shown. HEK293T cells co-transfected with b3AR, HA-
tagged Gas and GRK2 or Mock were incubated for 10 min with 10µM BRL37344, and cross-linking with 2.5mM dithiobis(succinimidyl propionate) was done. Cells were
lysed, and GRK2 was immunoprecipitated (IP) using anti-GRK2 antibodies followed by A/GPlus agarose beads incubation. Co-precipitated Gas was detected by western
blot using anti-HA antibodies. Total Gas was detected by western blot using anti-Ha or anti-Gas antibodies. (B) HEK293T-b3AR cells co-transfected with GRK2 wild type,
GRK2-K220R, GRK2-D110A, GRK2-R106A/K220R or RHPH(GRK2) were lysed, resolved by SDS-PAGE 12% and immunoblotted using anti-GRK2 or anti-b tubulin
antibodies as indicated. Image showed is representative of three independent experiments (upper panel). Transfected HEK293T cells were pre-treated during different time
periods with 10µM BRL37344. After that, cells were washed, incubated with IBMX for 3 min and challenged (stimulated response) or not (basal response) with 10µM
BRL37344 for 30 min. cAMP production was quantified as described underMaterials and Methods (lower panel). Data is shown as stimulated over basal response (S/B)
normalized respect to control (without pre-treatment) considered as 100% and represent mean ± SD (n=3). Best-fit values of the parameters are in the main text. (C) HEKT
Epac-SH187 transiently co-transfected with b3AR and H2R were pre-treated during 1 h with either 10µM BRL37344, 10µM amthamine or vehicle. After that, cells were
washed and challenged with 10µM BRL37344. cAMP response was constructed with the AUC values of 10-minute R/R0 i-cAMP response of time course of FRET changes
determined in FlexStation® 3 at 37°C as described inMaterials and Methods. Data is shown as stimulated over basal response (S/B) and analyzed by one-way ANOVA and
Dunnett post-test. ns, not significant; ***P < 0.001 respect to Ctrol. Results are mean ± SD (n=5).February 2020 | Volume 11 | Article 113
Echeverría et al. Regulation of b3-Adrenergic Receptor Signaling by GRK2protein) activity, which favors Ga inactivation and the other relies
on the ability of RGS domain to bind activated Ga protein subunit
precluding the activation of the effector protein (e.g. AC) (Sterne-
Marr et al., 2004). Considering that it has been demonstrated that
GRK2 has weak GAP activity (Carman et al., 1999) and based on
our findings where Gas co-immunoprecipitates with GRK2 after
b3AR stimulation, we hypothesize that the underlying mechanism
of the observedb3AR short-termdesensitizationmight be based onFrontiers in Pharmacology | www.frontiersin.org 11the effector antagonism mediated by the RH domain of GRK2.
Hence, b3AR regulation in HEK293T transfected cells might be
bimodal, including a fast inactivation of receptor response at the
level of G protein by RH mediated blockade of Gas signaling,
followed by a long-term desensitization by adenylyl cyclase
inactivation and Gas downregulation (Michel-Reher and Michel,
2013). These results agree with previous observations indicating
that the target in b3AR desensitization is not the receptor itselfFIGURE 5 | Involvement of RH domain of GRK2 in the regulation of b3AR response in cardiomyocytes. (A) Neonatal rat cardiomyocytes cells were incubated with IBMX for
3 min, treated with different concentrations of BRL37344 in the presence or not of 10µM of b3AR antagonist L748337 as indicated. Each data point represents the mean of
a single experiment and cAMP response in control or L748337 pre-incubated cells from the same experimental day are connected by lines (n=3). Data were analyzed by
two-way ANOVA followed by Bonferroni post-test. ns, not significant; *P < 0.05; **P < 0.01 respect to Ctrol. ns, not significant; ##P< 0.01 as indicated. (B) Neonatal rat
cardiomyocytes transfected with Mock or siRNA targeting endogenous b3AR were pre-treated with IBMX for 3 min and stimulated with 10µM BRL37344 for 30 min. Each
data point represents the mean of a single experiment and cAMP levels in basal o BRL stimulated cells from the same experimental day are connected by lines (n=3). Data
were analyzed by two-way ANOVA followed by Bonferroni post-test. ns not significant, *P < 0.05 respect to basal. (C, E) Neonatal cardiomyocytes cells transfected with
GRK2-K220R or GRK2-D110A were lysed, resolved by 12% SDS-PAGE and immunoblotted using anti-GRK2 or anti-b tubulin antibodies. Image showed is representative
of three independent experiments. (D, F) Cardiomyocytes transfected with Mock, GRK2-K220R (D) or GRK2-D110A (F) were pre-treated with IBMX for 3 min and
stimulated with BRL37344 for 30 min at indicated concentrations. Each data point represents the mean of a single experiment and cAMP response in Mock and K220R
(D) or Mock and D110A (F) transfected cells from the same experimental day are connected by lines (n=5). Data were analyzed by two-way ANOVA followed by Bonferroni
post-test. ns, not significant; ***P < 0.001 respect to Mock. ns, not significant; ##P < 0.01 as indicated. (G) Cardiomyocytes transfected with Mock or GRK2-D110A were
pre-exposed to 1µM BRL3734 for 30 min, washed, incubated with IBMX for 3 min and stimulated with 10µM BRL37344 for 30 min. Each data point represents the mean of
a single experiment and cAMP response in Mock and GRK2-D110A transfected cells from the same experimental day are connected by lines (n=5). Data is shown as
stimulated over basal response (S/B). Data were analyzed by two-way ANOVA followed by Bonferroni post-test. **P < 0.01 respect to Mock. #P < 0.05 as indicated. cAMP
production was quantified as described underMaterials and Methods.February 2020 | Volume 11 | Article 113
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2013). While long-termmechanisms might have a more profound
and generalized effect over signaling of GPCRs coupled to Gas, RH
driven desensitization by GRK2 might be more specific since
soluble GRK2 translocates to plasmatic membrane after receptor
activation, affecting only the signaling of the stimulated GPCR.
Consistently, in HEK293T cells transfected with H2R and b3AR
desensitization of H2R did not attenuate b3AR response, even
though both GPCRs share that they are desensitized by the RH
domain of GRK2 (Fernandez et al., 2011). Also, the possibility of
other members of RGS family taking place in b3AR signaling
regulation should be considered and further studied.
Endogenously expressing b3AR models yielded heterogeneous
results regarding receptor desensitization and in this context,
transfected cells allowed us to identify underlying molecular
mechanisms. However, HEK293T transfected cells may not be
representative of tissues that endogenously express b3AR. Previous
reports indicate that b3AR plays an important role in
cardiomyopathies. Its expression levels were shown to be increased
in human ischemic and dilated ventricles of failing hearts (Moniotte
et al., 2001). This increment was accompanied by a more prevailing
b3AR function over b1/2AR counterparts (Gauthier et al., 2000).
Based on that, it has been suggested a promising therapeutic strategy
to treatheart failurebasedon long-termb3ARstimulation thatwould
protect against the adverse remodelling mainly mediated by b1AR
response to the increased sympathetic activity (Engelhardt et al.,
1999; Cannavo and Koch, 2017). In this context, GRK2 takes
relevance, as chronic exposure to catecholamines is followed by its
overexpression in the failing heart (Campanile and Iaccarino, 2009).
Therefore, since pathological alteration of GRK2 levels and function
might alsobedetrimental forb3ARcardioprotective function,proper
identification and characterization of the mechanisms of b3AR
desensitization is of paramount importance. Accordingly, we
studied receptor response in a cardiac environment where
physiological levels of b3AR are expressed. Since cardiac cell lines
do not precisely depict the functional physiology of isolated
ventricular cardiomyocytes, we employed primary cardiomyocytes
culture as a representative model of cardiac signaling at the cellular
level and evaluated the relevance of RGS-GRK2mediated regulation
on b3AR response. Although b3AR has been described to
preferentially couple to Gai in the human heart in native
conditions, it has been proved to also couple to Gas-AC-PKA in
cardiac tissue of transgenic rodentmodel (Kohout et al., 2001) aswell
as in heterologous expression system and adipocytes (Soeder et al.,
1999). Our results indicate that in rat cardiomyocytes, activation of
endogenously expressed b3AR increases cAMP intracellular levels,
and b3AR undergoes short-term desensitization. We also observed
that over-expressionof adominantnegativemutantofRHdomainof
GRK2, increases receptor responsiveness and attenuates
desensitization, suggesting the involvement of this domain of
GRK2 in the regulation of cardiac expressed b3AR.
Although these findings agree with the mechanism described in
HEK293T cells some differences between models are observed and
the mechanism described in HEK293T cells may not be
extrapolated to cardiomyocytes. For example, it is noticeable that
RGS dominant negative mutants are more effective inFrontiers in Pharmacology | www.frontiersin.org 12cardiomyocytes (Figures 5D–G) and overexpression of RH
functional domain seems to have more radical effects in
HEK293T cells (Figure 4B). These apparent discrepancies could
be explained in terms of differences in the relative expression levels
of endogenous GRK2 between the two models. On the other hand,
no significant cAMP response to 1µM BRL37344 was observed in
cardiomyocytes. However, the efficacy of a ligand is directly related
to receptor density, and then, it is not surprising that a ligandproves
to be more efficacious in an overexpression system than in a not
transfected primary culture.
Overall, results presented here show the role of RH domain of
GRK2 in the desensitization of b3AR, a GPCR that has been
proposed as a therapeutic target for long term treatment of heart
failure. Additionally, mirabegron has been licensed as a first-in-
class b3AR agonist for the treatment of overactive bladder
syndrome and has shown to be well tolerated and effective. In
the same way, vibegron (Yoshida et al., 2018) is being studied for
the same purpose. However, treatment with these ligands do not
lead to resolution of the syndrome and long-term use of the
agonist is also needed to improve bladder symptoms. Although
mirabegron is used at nanomolar concentrations (Silva et al.,
2017), the existence of receptor desensitization has not been rule
out, and considering the results presented herein, further
understanding and characterization of the mechanisms involved
in b3AR desensitization would allow overcoming potential
limitations that chronic use of agonists may bring in a long-
term therapy of heart failure or overactive bladder syndrome.
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